期刊文献+

经皮微波消融治疗低风险甲状腺微小乳头状癌效果及对生活质量的影响 被引量:16

Efficacy of percutaneous microwave ablation on low-risk papillary thyroid microcarcinoma and impact on patient's life quality
在线阅读 下载PDF
导出
摘要 目的观察经皮微波消融治疗低风险甲状腺微小乳头状癌(PTMC)的效果和对患者生活质量的影响。方法对75例经病理证实的单发低风险(T1N0M0)PTMC患者行超声引导下经皮微波消融治疗。术后随访,分别于1、3、6、12、24个月观察治疗效果及并发症,并行躯体健康总评(PCS)、心理健康总评(MCS)和36项健康调查简表(SF-36)评分。结果75例均顺利完成手术。消融过程中4例出现短暂声嘶,2 h内恢复;15例自觉放射性耳根痛、颈部疼痛等,消融后立即缓解。术后24个月时治疗有效率100%(75/75),病灶消失率93.33%(70/75),无局部复发病例。术后1、3个月病灶最大径和体积均较术前增加,术后6、12、24个月病灶均较术前缩小(P均<0.05)。术前及术后各时间点促甲状腺激素(TSH)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)水平差异均无统计学意义(P均>0.05)。术前及术后不同时间点PCS得分差异无统计学意义(P>0.05),术后各时间点MCS得分及SF-36总分均高于术前(P均<0.05)。结论经皮消融治疗低风险PTMC安全、有效,并可提升患者生活质量。 Objective To observe the efficacy of percutaneous microwave ablation on low-risk papillary thyroid microcarcinoma(PTMC)and impact on patient's life quality.Methods Totally 75 pathologically confirmed patients with single low risk PTMC(T1N0M0)were treated with ultrasound-guided percutaneous microwave ablation and followed up at 1,3,6,12 and 24 months respectively after operation.The therapeutic effect and complications were observed,and score the physical component summary(PCS),mental component summary(MCS)and 36-item short form health survey(SF-36)scores were counted.Results The operation was successfully completed in all 75 patients.Four patients experienced temporary hoarseness during the ablation process and recovered within 2 h,while 15 patients complained of radiation-induced ear root pain,neck pain and other symptoms which immediately relieved after ablation.Twenty-four months after operation,the effective rate of treatment was 100%(75/75),the lesion disappearance rate was 93.33%(70/75),while no local recurrence occurred.The maximum diameter and volume of lesions increased 1 and 3 months after operation but decreased 6,12 and 24 months after operation(all P<0.05).There was no significant difference of thyroid stimulating hormone(TSH),free triiodothyronine(FT3)nor free thyroxine(FT4)levels among all time points(all P>0.05).PCS scores at different time points before and after operation showed no statistical significant difference(all P>0.05).MCS scores and SF-36 scores of all time points after operation were higher than those before operation(all P<0.05).Conclusion Percutaneous ablation is safe and effective for treating low risk PTMC,which can improve the patient's life quality.
作者 陈吉东 岳林先 熊晏群 顾毅 张惠 吴昊 贺伟 CHEN Jidong;YUE Linxian;XIONG Yanqun;GU Yi;ZHANG Hui;WU Hao;HE Wei(Ultrasound Medical Center,Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital,Chengdu 610072,China;Surgical Anesthesia Center,Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital,Chengdu 610072,China;Vascular Thyroid Surgery,Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital,Chengdu 610072,China)
出处 《中国介入影像与治疗学》 北大核心 2020年第10期577-580,共4页 Chinese Journal of Interventional Imaging and Therapy
基金 四川省科技厅重点研发项目(2020YFS0406)。
关键词 甲状腺癌 乳头状 超声检查 介入性 微波消融 生活质量 thyroid cancer,papillary ultrasonography,interventional microwave ablation quality of life
  • 相关文献

参考文献8

二级参考文献88

  • 1潘景升,刘生,罗葆明,马健鸿,王浩虎,邓宝雯.介入性超声治疗甲状腺良性结节的临床应用[J].岭南现代临床外科,2010,10(3):170-171. 被引量:4
  • 2周学平,杨广顺,丛文铭,卢军华,张树辉,宗明.原发性肝癌瘤周肝组织内微转移的回顾性与前瞻性研究[J].中华肝胆外科杂志,2005,11(8):510-514. 被引量:19
  • 3American Thyroid Association (ATA) Guidelines Taskforce on Thy- roid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association manage- ment guidelines for patients with thyroid nodules and differentiat- ed thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
  • 4Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid as- sociation management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid as- sociation guidelines task force on thyroid nodules and differentiat- ed thyroid cancer[J]. Thyroid, 2016, 26(1):1-133.
  • 5Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2.2014[J]. J Natl Compr Canc Netw, 2014, 12(12):1671-1680.
  • 6Xing MZ. Molecular pathogenesis and mechanisms of thyroid can- cer[J]. Nat Rev Cancer, 2013, 13(3):184-199.
  • 7De Biase D, Gandolfi G, Ragazzi M, et al. TERT promoter mutations in papillary thyroid microcarcinomas[J]. Thyroid, 2015, 25(9):1013- 1019.
  • 8Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients[J]. World J Surg, 2010, 34(1):28-35.
  • 9Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid [J]. Thyroid, 2003, 13(4):381-387.
  • 10Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer[J]. J Clin Oncol, 2015, 33(1):42-50.

共引文献518

同被引文献139

引证文献16

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部